The active drug in Bydureon BCise is exenatide in an extended-release form. Bydureon BCise is classified as a glucagon-like peptide-1 (GLP-1) agonist. Bydureon BCise isn’t currently available as a ...
Bydureon BCise was discontinued by its manufacturer AstraZeneca on October 28, 2024. This drug is no longer available in the United States. Discontinuation of Bydureon BCise was a business decision by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results